DOI QR코드

DOI QR Code

Treatment with a Small Synthetic Compound, KMU-193, induces Apoptosis in A549 Human Lung Carcinoma Cells through p53 Up-Regulation

  • Choi, Eun Young (Department of Internal Medicine, Yeungnam University College of Medicine) ;
  • Shin, Kyeong-Cheol (Department of Internal Medicine, Yeungnam University College of Medicine) ;
  • Lee, Jinho (Department of Chemistry, Keimyung University) ;
  • Kwon, Taeg Kyu (Department of Immunology, School of Medicine, Keimyung University) ;
  • Kim, Shin (Department of Immunology, School of Medicine, Keimyung University) ;
  • Park, Jong-Wook (Department of Immunology, School of Medicine, Keimyung University)
  • Published : 2015.09.02

Abstract

Despite recent advances in therapeutic strategies for lung cancer, mortality still is increasing. In the present study, we investigated the anti-cancer effects of KMU-193, 2-(4-Ethoxy-phenyl)-N-{5-[2-fluoro-4-(4-methylpiperazine-1-carbonyl)-phenylamino]-1H-indazol-3-yl}-acetamide in a human non-small cell lung cancer cell line A549. KMU-193 strongly inhibited the proliferation of A549 cells, but it did not have anti-proliferative effect in other types of cancer cell lines. KMU-193 further induced apoptosis in association with activation of caspase-3 and cleavage of PLC-${\gamma}1$. However, KMU-193 had no apoptotic effect in untransformed cells such as TMCK-1 and BEAS-2B. Interestingly, pretreatment with z-VAD-fmk, a pan-caspase inhibitor, strongly abrogated KMU-193-induced apoptosis. KMU-193 treatment enhanced the expression levels of p53 and PUMA. Importantly, p53 siRNA transfection attenuated KMU-193-induced apoptosis. Collectively, these results for the first time demonstrate that KMU-193 has strong apoptotic effects on A549 cells and these are largely mediated through caspase-3- and p53-dependent pathways.

Acknowledgement

Supported by : National Research Foundation of Korea (NRF)

References

  1. Ahmad N, Feyes DK, Nieminen AL, et al (1997). Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst, 89, 1881-6. https://doi.org/10.1093/jnci/89.24.1881
  2. Amaral JD, Xavier JM, Steer CJ, et al (2010). The role of p53 in apoptosis. Discov Med, 9, 145-52.
  3. Bae SS, Perry DK, Oh YS, et al (2000). Proteolytic cleavage of phospholipase C-gamma1 during apoptosis in Molt-4 cells. FASEB J, 14, 1083-92.
  4. Binder D, Hegenbarth K (2013). Emerging options for the management of non-small cell lung cancer. Clin Med Insights Oncol, 7, 221-34.
  5. Donnerstag B, Ohlenschlager G, Cinatl J, et al (1996). Reduced glutathione and S-acetylglutathione as selective apoptosisinducing agents in cancer therapy. Cancer Lett, 110, 63-70. https://doi.org/10.1016/S0304-3835(96)04461-8
  6. Emoto Y, Manome Y, Meinhardt G, et al (1995). Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J, 14, 6148-56.
  7. Feng Z (2010). p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harb Perspect Biol, 2, 1057. https://doi.org/10.1101/cshperspect.a001057
  8. Fossella F, Pereira JR, von Pawel J, et al (2003). Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol, 21, 3016-24. https://doi.org/10.1200/JCO.2003.12.046
  9. Fridman JS, Lowe SW (2003). Control of apoptosis by p53. Oncogene, 22, 9030-40. https://doi.org/10.1038/sj.onc.1207116
  10. Hong H, Park YK, Park JW, et al (2012). BAI, a 3-aminoindazole derivative, inhibits interleukin-1beta-induced expression of cyclooxygenase-2 in A549 human airway cells. Int J Mol Med, 29, 454-60.
  11. Jemal A, Center MM, DeSantis C, et al (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19, 1893-907. https://doi.org/10.1158/1055-9965.EPI-10-0437
  12. Kim S, Lee J, Jang BC, et al (2013). BAI, a novel cyclindependent kinase inhibitor induces apoptosis in A549 cells through activation of caspases and inactivation of Akt. J Cell Biochem, 114, 282-93. https://doi.org/10.1002/jcb.24314
  13. Lee J, Choi H, Kim KH, et al (2008). Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett, 18, 2292-5. https://doi.org/10.1016/j.bmcl.2008.03.002
  14. Li Q, Ren FQ, Yang CL, et al (2015). Anti-proliferation effects of isorhamnetin on lung cancer cells in vitro and in vivo. Asian Pac J Cancer Prev, 16, 3035-42. https://doi.org/10.7314/APJCP.2015.16.7.3035
  15. Liu CJ, Zhang XL, Luo DY, et al (2015). Exogenous p53 upregulated modulator of apoptosis (PUMA) decreases growth of lung cancer A549 cells. Asian Pac J Cancer Prev, 16, 741-6. https://doi.org/10.7314/APJCP.2015.16.2.741
  16. Logue SE, Martin SJ (2008). Caspase activation cascades in apoptosis. Biochem Soc Trans, 36, 1-9. https://doi.org/10.1042/BST0360001
  17. Nakano K, Vousden KH (2001). PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell, 7, 683-94. https://doi.org/10.1016/S1097-2765(01)00214-3
  18. Oh JH, Park EJ, Park JW, et al (2010). A novel cyclin-dependent kinase inhibitor down-regulates tumor necrosis factor-alpha (TNF-alpha)-induced expression of cell adhesion molecules by inhibition of NF-kappaB activation in human pulmonary epithelial cells. Int Immunopharmacol, 10, 572-9. https://doi.org/10.1016/j.intimp.2010.02.004
  19. Rufini A, Tucci P, Celardo I, et al (2013). Senescence and aging: the critical roles of p53. Oncogene, 32, 5129-43. https://doi.org/10.1038/onc.2012.640
  20. Saika K, Machii R (2012). Cancer mortality attributable to tobacco by region based on the WHO Global Report. Jpn J Clin Oncol, 42, 771-2. https://doi.org/10.1093/jjco/hys117
  21. Scagliotti GV, De Marinis F, Rinaldi M, et al (2002). Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol, 20, 4285-91. https://doi.org/10.1200/JCO.2002.02.068
  22. Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
  23. Shin HC, Song DW, Baek WK, et al (2009). Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor. Chemotherapy, 55, 353-62. https://doi.org/10.1159/000232450
  24. Siegel R, DeSantis C, Virgo K, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 62, 220-41. https://doi.org/10.3322/caac.21149
  25. Sledge GW, Jr. (2005). What is targeted therapy? J Clin Oncol, 23, 1614-5. https://doi.org/10.1200/JCO.2005.01.016
  26. Wu DM, Zhang P, Xu GC, et al (2015). Pemetrexed induces G1 phase arrest and apoptosis through inhi`biting Akt activation in human non small lung cancer cell line A549. Asian Pac J Cancer Prev, 16, 1507-13. https://doi.org/10.7314/APJCP.2015.16.4.1507
  27. Xu Y, Zhang Y, Ma S (2011). EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer, 73, 249-55. https://doi.org/10.1016/j.lungcan.2011.04.017

Cited by

  1. Growth inhibitory and apoptosis-inducing effects of allergen-free Rhus verniciflua Stokes extract on A549 human lung cancer cells vol.36, pp.5, 2016, https://doi.org/10.3892/or.2016.5131